Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 75Lung Neoplasms 48Small Cell Lung Carcinoma 11Neoplasms 10NSCLC 8Colorectal Neoplasms 7Prostatic Neoplasms 6Ovarian Neoplasms 6Brain Neoplasms 6Mesothelioma 5Breast Neoplasms 5Pancreatic Neoplasms 4Neoplasm Metastasis 4Melanoma 4Head and Neck Neoplasms 4Adenocarcinoma of Lung 4Liver Neoplasms 3Hematologic Neoplasms 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Sarcoma 2Recurrence 2Neoplasms by Site 2Neoplasms by Histologic Type 2Multiple Myeloma 2Laryngeal Neoplasms 2

Interventions

pembrolizumab 1Pemetrexed 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Nonsquamous Non-small Cell Lung Cancer × Thoracic × Clear all
NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Taizhou Hanzhong biomedical co. LTD

Phase 2/3 Unknown
700 enrolled
Thoracic

Nonsquamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡